Chapters

Transcript

Video

As a lead investigator for both FH and ASCVD-focused trials evaluating PCSK9 inhibitors, what is your interpretation of the data confirming regimen adherence and compliance with these injectable agents?

As a lead investigator for both FH and ASCVD-focused trials evaluating PCSK9 inhibitors, what is your interpretation of the data confirming regimen adherence and compliance with these injectable agents? 


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Stephen Nicholls, MD

Stephen Nicholls, MD

SAHMRI Deputy Director and Heart Foundation Heart Health Theme Leader
Professor of Cardiology
University of Adelaide
Consultant Cardiologist
Royal Adelaide Hospital
Adelaide, Australia